West Pharmaceutical Services, Inc.
WST
Category
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 47.60 | -1.91% |
| 2024 | 48.53 | 10.08% |
| 2023 | 44.09 | 47.53% |
| 2022 | 29.89 | -43.32% |
| 2021 | 52.73 | -12.81% |
| 2020 | 60.48 | 31.40% |
| 2019 | 46.03 | 31.45% |
| 2018 | 35.01 | -27.64% |
| 2017 | 48.39 | 11.74% |
| 2016 | 43.30 | -4.53% |
| 2015 | 45.35 | 52.71% |
| 2014 | 29.70 | -2.33% |
| 2013 | 30.41 | 31.79% |
| 2012 | 23.07 | 36.16% |
| 2011 | 16.94 | -19.35% |
| 2010 | 21.01 | 18.63% |
| 2009 | 17.71 | 24.43% |
| 2008 | 14.23 | -24.20% |
| 2007 | 18.78 | -23.63% |
| 2006 | 24.59 | 43.98% |
| 2005 | 17.08 | -55.90% |
| 2004 | 38.72 | 151.44% |
| 2003 | 15.40 | -19.63% |
| 2002 | 19.16 | -126.13% |
| 2001 | -73.33 | -133.16% |
| 2000 | 221.15 | 0.00% |
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 47.48 | -0.25% |
US
|
|
| 27.43 | -42.39% |
FR
|
|
| - | - |
JP
|
|
| 56.89 | 19.51% |
US
|
|
| - | - |
CH
|
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.